RxDoctor Payments Data

Thomas Sabalaske, DO

Family Medicine · Feasterville, PANPI 1831161561

Payments from drug & device makers

$10,696in general payments, 2019–2025

Across 638 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$937
  • Lilly USA, LLC$746
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$10,62499%
  • Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,696 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$227,202
Medicare patients
345
Services billed
3,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$126,885
OzempicSemaglutide74$102,717
FarxigaDapagliflozin Propanediol37$41,619
JardianceEmpagliflozin24$40,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$30,966
TrulicityDulaglutide22$29,808
EmsamSelegiline12$24,512
JanuviaSitagliptin Phosphate20$23,011
Tresiba Flextouch U-200Insulin Degludec17$15,345
Valsartan210$8,812
Lagevrio (Eua)Molnupiravir17$7,395
Atorvastatin Calcium435$6,783
Praluent PenAlirocumab11$5,746
Levothyroxine Sodium252$4,467
Rosuvastatin Calcium195$3,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,529$126,885114 claims
Novo NordiskOzempic$937$102,71774 claims
AstraZenecaFarxiga$1,064$41,61937 claims
Boehringer IngelheimJardiance$535$40,20324 claims
GSKTrelegy Ellipta$1,011$30,96630 claims
MerckJanuvia, Lagevrio (Eua)$292$30,40637 claims
Lilly USA, LLCTrulicity$746$29,80822 claims
AbbVieSynthroid$1,061$1,31039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Feasterville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →